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Circular RNA circPRMT5 is upregulated in breast cancer and is required for cell
proliferation and migration
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Background/aim: To evaluate the role of cyclic protein arginine methyltransferase 5 (circPRMT5) in the occurrence and development
of breast cancer (BC).
Materials and methods: A total of 90 BC patients who underwent radical mastectomy and 40 age-matched healthy female controls
were recruited in the Second People’s Hospital of China Three Gorges University, Yichang Second People’s Hospital from 2017 to 2020.
Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression levels of circPRMT5 in
BC tissues, serum, normal breast cell line (MCF-10A), and BC cell line (T47D, MCF-7, BT549, Hs-578T, and MDA-MB-231, MDAMB-468). The associations between circPRMT5 expression level and age, tumor size, degree of differentiation, TNM stage, distant
metastasis, estrogen receptor (ER) or progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status were
analyzed. BC cell lines with circPRMT5 knockdown or overexpression were subject to CCK-8 cell proliferation assay, and transwell cell
invasion/migration assay.
Results: CircPRMT5 expression in BC tissue was higher than that in adjacent normal breast tissue. Consistently, the expression level of
circPRMT5 was also elevated in serum samples collected from BC patients when compared with healthy controls. And in multiple breast
cancer cell lines, circPRMT5 was upregulated as compared to normal breast epithelial MCF-10A cells. CircPRMT5 expression level
was correlated with tumor size, TNM stage, lymph node metastasis distant metastasis, but no correlation was observed with ER, PR,
HER2 status. Overexpression of circPRMT5 promoted the proliferation, invasion, and migration of MCF7 cells; while the knockdown
of circPRMT5 inhibited cell proliferation, invasion, and migration.
Conclusion: CircPRMT5 seems to act as an oncogene in the progression of BC. Our data suggest that CircPRMT5 may be used as a
biomarker for the diagnosis, prognosis evaluation, and targeted therapy of breast cancer.
Key words: Breast cancer, circPRMT5, diagnosis, prognosis, proliferation, metastasis

1. Introduction
Breast cancer (BC) is one of the malignant tumors with
the highest incidence in women [1]. The annual incidence
and death toll account for 23% and 14% of the global
diagnosis and deaths respectively, ranking as one of the

leading causes of cancer-related fatality in females [2]. At
present, there is no good biomarker for early diagnosis and
prognostic evaluation of BC. Uncontrolled proliferation,
invasion, and metastasis are important biological
characteristics of BC cells, accounting for the recurrence
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and poor prognosis after initial treatment [3]. Distant
metastasis has been considered one of the main causes of
BC-related death [4]. Bone metastasis occurs in 70% of BC
cases, which often correlates with a poor prognosis [5].
Therefore, the investigation of the molecular mechanism
of BC growth and metastasis will provide new insight into
novel biomarkers and the development of targeted therapy
for effective BC diagnosis and treatment.
Circular RNA (circRNA) is a class of noncoding RNA
molecule with a closed loop structure. The mechanism
of circRNA molecule formation mainly involves “exon
skipping” and “reverse shearing” of precursor mRNA
[6]. Early studies proposed that circRNA molecules are
redundant and nonfunctional molecules [7]. In recent
years, the advancement of the deep sequencing technology
enables the identification of a large number of exon or intron
of circRNA, indicating that circRNAs are functional RNA
molecules with regulatory properties [8,9]. Furthermore,
the unique stable closed-loop structure of circRNA makes
it a promising marker for clinical diagnosis. Indeed,
several studies have revealed that circRNA molecules can
be detected in the plasma of cancer patients, which are
closely related to the survival of the patients [10–12].
CircPRMT5 (hsa_circ_0031242) is a circRNA
implicated in the occurrence and development of a variety
of malignant tumors [13, 14]. CircPRMT5 has been
found to be highly expressed in hepatocellular carcinoma,
bladder cancer, and nonsmall cell lung cancer, and it
acts as an oncogene [15,16]. However, the role and the
regulatory mechanism of circPRMT5 in BC remain to be
uncovered. In this study, we collected BC tumor samples
and adjacent normal tissues, as well as the serum samples
from BC patients and healthy controls. We evaluated the
expression level of circPRMT5 in BC tumor tissues and the
serum sample of BC patients. We further investigated the
functional role of circPRMT5 overexpression in BC cells.
2. Materials and methods
2.1. Patients and tissue samples
This study was approved by the Institutional Review
Board of Second People’s Hospital of China Three Gorges
University, Yichang Second People’s Hospital (LL-2016011). Patient samples were obtained after written informed
consent had been obtained, and all procedures were
performed in this study involving human participants were
in accordance with the Declaration of Helsinki (as revised
in 2013). We collected BC tumor tissues and normal tissue
adjacent to the tumor (paracancer tissues) from 90 patients
during surgical resection at the Second People’s Hospital of
China Three Gorges University, Yichang Second People’s
Hospital between 2017 and 2020 (age range 18–80 years).
Specimens were immediately frozen in liquid nitrogen
after resection and stored at –80 °C until usage. Each
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sample (5 g) was used for total RNA extraction and the
expression of circPRMT5 in these samples was compared
by RT-qPCR.
Inclusion criteria: Subjects who were able to provide
written informed consent to participate in the study
on a voluntary basis; subjects had no other concurrent
malignant tumors; subjects with primary tumors that
could be surgically removed, no blood-related diseases
and infectious diseases were observed. Exclusion criteria:
Subjects who were undergoing chemotherapy; subjects
had fatal diseases; subjects with benign tumors, and
patients with nonprimary breast lesions. All collected
tumor tissues were diagnosed by three pathologists. The
tumor site was confirmed by hematoxylin-eosin (H&E)
staining, and then the tumor and paracancer tissues were
separated. H&E staining was performed for a second time
to further confirm the successful separation of tumor
and nontumor tissues (see the flowchart in Figure 1). The
pathological diagnosis of breast cancer was performed
according to the WHO Classification (https://radiopaedia.
org/articles/who-classification-of-tumors-of-the-breast)
and the Elston and Ellis grading system (http://tvmouse.
ucdavis.edu/bcancercd/311/grading_diagram.html).
Additionally, 2 weeks before the surgical operation,
40 out of 90 BC patients were randomly selected and the
circPRMT5 expression level in serum was compared to
that of 40 age-matched healthy female volunteers enrolled
in the same hospital (see the flowchart in Figure 1).
Peripheral venous blood samples were collected 2 weeks
before the surgical operation in the BC patients to detect the
expression of circPRMT5 in serum. All the 90 BC patients
were followed up regularly by telephone every month after
surgery, and the recurrence and survival status of patients
were recorded. Relapse-free survival time was defined as
the time interval from the date of surgery to the date of
the first clinical diagnosis of recurrence, and censored data
was defined as the time interval from the date of surgery to
the date of the last follow-up of the patients.
2.2. Cell culture and transfection
Human BC cell lines (T47D, MCF-7, BT549, Hs-578T
and MDA-MB-231, MDA-MB-468) and normal breast
epithelial MCF-10A cells were obtained from the Cell
Bank of Chinese Academy of Sciences (Shanghai, China).
Cells were cultured in RPMI-1640 medium (Gibco,
USA) supplemented with 10% fetal bovine serum and
1% penicillin/streptomycin at 37 °C in a humidified cell
incubator with 5% CO2. Cell transfection procedure was
performed as described below:
MCF7 cells were trypsinized and centrifuged at 500 ×
g for 5 min, and then resuspended in complete medium.
Cells were seeded into a 6-well plate at a density of 5 ×
105 cells/well and incubated overnight. When the cell
density reached 60% to 80% confluency, transfection
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Figure 1. Flow diagram showing patient enrollment and clinical sample collection.

of siRNA (small interfering RNA) was conducted
using Lipofectamine™ RNAiMAX transfection reagent
(Invitrogen, USA) according to the manufacturer’s
manual. Briefly, 4 μL of nonspecific siRNA (si-NC)
or siRNA targeting circPRMT5 (si-circPRMT5) (100
nM) were diluted with 200 μL of opti-MEM medium
(Thermo Fisher Scientific, USA), respectively. Then 8
μL of RNAiMAX transfection reagent was mixed with
200 μL of opti-MEM medium. The diluted siRNA was
mixed with transfection reagent at room temperature for
15 min, and then added to MCF7 cells. After 6 h, cells
were replenished with fresh medium for 36 h incubation
before subsequent experiments. siRNA targeting
circPRMT5 and siRNA control were purchased from
Genscript Biotech (Nanjing, China). The oligonucleotide
sequences are as follows: si-circPRMT5 sense chain:
5’-CUCCUGACCUCAGUUCAUCTT-3’,
antisense
strand: 5’-GAUGAACUGAGGUCAGGAGTT-3’.
2.3. Overexpression of circPRMT5
The control vector and circPRMT5 overexpression plasmid
pCDNA3.1-circPRMT5 were purchased from Genscript
Biotech (Nanjing, China). The day before transfection,
MCF7 cells were seeded in a 6-well plate at a density
of 6 × 105 cells per well to ensure that the cells reached
70% confluence before transfection. Lipofectamine 2000
reagent (5 μL) (Thermo Fisher Scientific, USA) was diluted
with 125 μL of opti-MEM medium. Plasmid (2.5 μg) was
diluted with 125 μL of opti-MEM medium. The diluted
plasmid was mixed with Lipofectamine 2000 reagent (1:1)
and incubated for 15 min at room temperature. The mixed
plasmid liposome complex was added to the cell culture.
After 6 h, fresh medium was replaced and cells were
further cultured for 36 h before following experiments.

2.4. RNA isolation and RT-qPCR
Total RNA was isolated from serum, tissue, and BC cell
lines using a Trizol reagent (Takara Biotechnology Co.,
Ltd., Dalian, China) according to the manufacturer’s
instructions. The purity of the extracted RNA was
determined by spectrophotometry at 260/280 nm,
and 5µg purified total RNA was reverse transcribed
into cDNA using the PrimeScript RT reagent kit (Cat#
RR037A, Takara, China). Quantitative real-time PCR
(qPCR) reactions were performed on ABI Prism 7500
real time PCR instrument (Applied Biosystems, USA)
using the SYBR Green PCR Master Mix (Takara, Japan).
The PCR conditions were as follows: one cycle of 50°C
for 2 min and 95°C for 10 min, followed by 40 cycles of
95 °C for 30 s and 60 °C for 30 s. The relative expression
of the target gene was determined by 2−ΔΔCt method.
GAPDH was selected as the internal control gene for
normalizing the expression. The primer sequences used
for RT-qPCR were listed below [16]: GAPDH forward
primer 5’- TCCCATCACCATCTTCCAGG -3’, reverse
primer 5’-GATGACCCTTTTGGCTCCC-3’; circPRMT5
forward primer 5’- TACCATTGGCCTCTAGCCCT-3’,
reverse primer 5’- CAAGGGGAATCACAGCCCAT-3’.
2.5. CCK-8 (cell counting kit-8) assay for cell proliferation
CCK-8 cell proliferation assay was performed according
to a previous study [17]. Cell counting kit-8 (CCK-8;
Dojindo, Japan) assay was used for the cell proliferation
capacity. Cells were seeded in a 96-well plate at a density
of 3000 cells/well, and cultured for indicated time period.
CCK-8 solution (10 μL) was added to the cell culture at
each time point, the plates were incubated for 3 h. CCK-8
(10 μL) reagent was added to each well at the indicated
time point and incubated in the incubator for 1 h. A
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Figure 2: Expression of circPRMT5 in BC. A: the RT-qPCR method detects the expression level of circPRMT5 in 90 pairs of BC
tumor tissues and adjacent normal tissues (normal, paracancer tissues). CircPRMT5 expression was significantly increased in BC tumor
samples, p < 0.001. B: RT-qPCR method was used to measure the expression level of circPRMT5 in BC cell lines (T47D, MCF-7, BT549,
Hs-578T, MDA-MB-231, and MDA-MB-468) and normal breast epithelial MCF-10A cells. The expression of circPRMT5 in BC cell lines
were significantly elevated, p < 0.01. C: RT-qPCR method was used to detect the expression level of circPRMT5 in the serum samples
of 40 cases of BC patients and 40 normal healthy controls. CircPRMT5 expression in BC serum was significantly increased, p < 0.001.
D: Receiver operating characteristics (ROC) curve of circPRMT5 expression level for predicting the BC cancer from the 90 BC tumor
samples and 90 paracancerous tissues. AUC (area under the curve) >0.8 indicates a good prediction with p < 0.001.

microplate reader (Bio-Rad, CA, USA) was used to detect
the absorbance value (OD value) in each well at 450 nm.
2.6. Cell migration and invasion assays
Cell migration and invasion assays were performed
according to a previous study [18]. Corning Transwell
polycarbonate membrane cell culture inserts with 8.0-μm
pores were uncoated for migration assay, or coated with
50 µL of BD Matrigel Basement Membrane Matrix (BD
Biosciences, USA) diluted 1:3 with FBS-free DMEM (fetal
bovine serum free Dulbecco’s Modified Eagle Medium)
for invasion assay. Cells were trypsinized and then
resuspended in serum-free medium. 2 × 104 cells were
seeded in the top chamber with serum-free medium and
allowed to migrate toward serum-containing medium in
the lower chamber for 24 h. Then cells were fixed in 4%
paraformaldehyde and stained with 0.01% crystal violet
(AS1086, ASPEN, China) for 10 min. After wiping the
cells remaining in the upper chamber with cotton swabs,
the migratory or invasive cells were imaged and counted
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using a Leica AM6000 microscope (Leica Microsystems,
Germany). The numbers of migratory or invasive cells
were calculated as the average numbers of five random
fields per well under 100X magnification.
2.7. Statistical analysis
Statistical analyses were performed with SPSS 20.0 software
(IBM SPSS, Armonk, NY, USA). All the experiments were
repeated three times. CircPRMT5 expression in tissues
was examined in 90 pairs of cancer and paracancerous
normal tissues; circPRMT5 expression in serum was
analyzed from the blood samples of 40 BC patients and
40 healthy controls. The association between circPRMT5
expression in cancer tissues and the clinic pathological
parameters was evaluated with chi-square analysis. The
statistical difference between the two groups was compared
using unpaired student’s t-tests. Comparisons among
multiple groups were analyzed using one-way analysis of
variance (ANOVA) with Tukey’s post hoc test for pairwise
comparison. Comparisons of data at multiple time
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Figure 3. Relationship between circPRMT5 and prognosis of BC patients. A: Kaplan–Meier survival curve was used to assess the overall
survival of BC patients in circPRMT5 low expression group (n = 45) and circPRMT5 high expression group (n = 45). 90 patients were
divided into low and high expression group based on the median value of circPRMT5 expression detect by qPCR in Figure 1A. BC
patients in the circPRMT5 high expression group showed a poorer survival than that of low expression group, p < 0.001. B: Kaplan–
Meier survival curve was used to evaluate the disease-free survival time of BC patients in circPRMT5 low expression group (n = 45)
and the circPRMT5 high expression group (n = 45). BC patients in the circPRMT5 high expression group had worse progression-free
survival than that of low expression group, p < 0.01.
Table. Correlations of CircPRMT5 expression with clinicopathologic features of breast cancer.

Parameters

Age
Tumor size
Differentiation
TNM stage
Lymph node metastasis
Distant metastasis
ER status
PR status
HER-2 status

Total

CircPRMT5
Low/high

>50

38

15

23

≤50

52

30

22

>2cm

34

25

9

≤ 2cm

56

20

36

High (well)

36

28

8

Low (poor)

54

17

37

I—II

39

28

11

III—IV

51

17

34

Negative

43

31

12

Positive

47

14

33

M0

58

39

19

M1

32

6

26

Positive

28

15

13

Negative

62

30

32

Positive

26

9

17

Negative

64

36

28

Positive

26

11

15

Negative

64

34

30

points were examined using two-way ANOVA. Kaplan
Meier Curve and log-rank test were used to compare the
cumulative survival rates in 90 BC patients. Data were
reported as the mean ± standard deviation (SD). P < 0.05
was considered to be statistically different.

P-value

0.088
0.001
0.001
0.001
0.001
0.001
0.649
0.063
0.352

3. Results
3.1. Expression of circPRMT5 in BC
To evaluate circPRMT5 expression in BC tumor
samples, we used RT-qPCR to compare the expression
level of circPRMT5 in 90 pairs of BC tissues and paired
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Figure 4: Functional assay of circPRMT5 overexpression on proliferation, invasion, and migration in MCF-7 cell line. A: RT-qPCR method
was conducted to detect the overexpression efficiency compared with vector. A: transfection with pcDNA3.1-circPRMT5 can effectively
overexpress circPRMT5 in cells, p < 0.01. B: CCK-8 method detects the light absorption value of 0h, 24h, 48h, and 72h at 450nm wavelength
in different groups (vector and pCDNA3.1-circPRMT5) in MCF7 cells. C: Transwell chamber (without matrigel) experiment was used to
test the migration ability in different groups (vector and pCDNA3.1-circPRMT5) of MCF7 cells. D: Transwell chamber (adding Matrigel)
experiment to detect the invasion ability in different groups (vector and pCDNA3.1-circPRMT5) of MCF7 cells.

paracancerous tissues. The results showed that circPRMT5
expression in BC tumors was significantly higher than
that of paracancerous tissues (P < 0.001, Figure 2A).
Consistently, circPRMT5 expression level in multiple
BC cell lines was also significantly increased than that in
normal cells (P < 0.01, Figure 2B). In addition, the levels
of circPRMT5 collected from serum in BC patients were
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also elevated when compared with healthy controls (P
< 0.001, Figure 2C). Moreover, the receiver operating
characteristics (ROC) curve of circPRMT5 expression level
was used for predicting the BC cancer status from 90 BC
tumor samples and 90 paracancerous tissues. AUC (area
under the curve) >0.8 indicates that circPRMT5 expression
with a cut-off value of 3.0 could be a good predictor for
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Figure 5: Functional assay of circPRMT5 overexpression on proliferation, invasion, and migration in MDA-MB-231cell line. A: Select the
BC cell line with the highest circPRMT5 expression (MDA-MB-231) from the results in Figure 1B for knockdown using si-circPRMT5,
and the RT-qPCR method detects knockdown efficiency. B: CCK-8 method detects the light absorption value of 0h, 24h, 48h, and 72h
in different groups (si-NC and si-circPRMT5) at 450nm wavelength in MDA-MB-231 cells. C: Transwell chamber (without matrigel)
experiment checks the migration ability of different groups (si-NC and si-circPRMT5) of MDA-MB-231 cells. D: Transwell chamber
(adding Matrigel) experiment to detect the invasion ability of different groups (si-NC and si-circPRMT5) of MDA-MB-231 cells.

breast cancer with a 78.6% sensitivity and 91.3% specificity
(Figure 2D). As shown in Table, 90 patients were divided
into low and high expression groups based on the median
value of circPRMT5 expression, and a high circPRMT5
expression level was associated with tumor maximum
diameter, degree of differentiation, TNM staging, lymph
node metastasis distant metastasis (P < 0.05). However,

circPRMT5 expression level was not associated with ER,
PR, HER2 status (P > 0.05) (Table).
3.2. Relationship between circPRMT5 and prognosis of
BC
To examine whether circPRMT5 expression level is
correlated with the prognosis of BC patients, we divided
the 90 patients into low expression group (n = 45) and
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high expression group (n = 45) based on the median value
of circPRMT5 expression detected by qPCR in Figure
1A. From the Kaplan–Meier survival curve, the overall
survival time and progression-free survival time of BC
patients in the circPRMT5 high expression group were
significantly shorter than that of the low expression group
(P < 0.001) (Figure 3). Taken together, the data suggest that
circPRMT5 is upregulated in BC and higher circPRMT5
expression correlates with a poor prognosis in BC patients.
3.3. Functional analysis of circPRMT5 overexpression
and silencing on proliferation, invasion, and migration
in BC cell line
From the results in Figure 1B, MCF7 cells showed a
relatively lower expression level of circPRMT5 than other
BC cell lines. We selected MCF7 cell line for overexpression
experiment using plasmid pCDNA3.1-circPRMT5. The
functional effects of circPRMT5 in the proliferation,
invasion, and migration were analyzed. RT-qPCR analysis
showed that transfection of pCDNA3.1-circPRMT5 was
capable to increase circPRMT5 expression by more than
four times in MCF7 cells (Figure 4A). CCK8 proliferation
assay showed that the overexpression of circPRMT5 could
promote cell proliferation (Figure 4B). Transwell migration
and invasion assays demonstrated that circPRMT5
overexpression enhanced the migration and invasion
ability of MCF7 cells (Figure 4C and D). Collectively, these
results indicated that elevated circPRMT5 expression
promotes cell proliferation, migration, and invasion in BC
cells.
To further confirm an indispensable role of circPRMT5
in BC cells, we knocked down circPRMT5 using siRNA
specifically targeting circPRMT5 in MDA-MB-231 cells
(Figure 5A). In comparison with the control group, the
proliferation of MDA-MB-231 cells with circPRMT5
knockdown was significantly suppressed (Figure 5B).
Cell migration and invasion assay further showed that the
number of migratory and invasive BC cells were largely
reduced after circPRMT5 silencing (Figure 5 C and D).
Taken together, these results suggest that circPRMT5 is
indispensable for supporting cell proliferation, migration,
and invasion in BC cells.
4. Discussion
In the study, we found that circPRMT5 was upregulated
in BC tissue as compared to adjacent normal breast tissue.
Consistently, circPRMT5 was also upregulated in serum
samples collected from BC patients when compared
with healthy controls. Importantly, a higher circPRMT5
expression level correlated with a poor prognosis in BC
patients. The overexpression of circPRMT5 in BC cells
promoted the proliferation, invasion, and migration;
while the knockdown of circPRMT5 inhibited cell
proliferation, invasion, and migration. These data suggest
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that circPRMT5 functions as an oncogenic factor in BC.
Many risk factors including age, hormone levels,
fertility, breastfeeding, and gene mutations have been
reported to be responsible for BC occurrence [19,20]. The
metastasis of the Her2-negative invasive breast cancer cells
is linked with poor prognosis [21, 22]. Previous studies
have been revealed genetic mutations contributing to
BC predisposition. Mutations or dysregulation of tumorsuppressor genes, such as BRCA-1, BRCA-2, p53, and PTEN
play an important role in the initiation and development of
BC [23–25]. Importantly, accumulating evidence uncovers
the critical role of noncoding RNA such cicrRNAs in the
progression of BC, which may regulate different biological
processes by sponging microRNA. For example, the
overexpression of circ-ABCB10 and circ_001783 were
found to facilitate BC progression through sponging miR1271 and miR-200c-3p, respectively [26, 27]. In addition,
circ_0003645 was shown to promote BC proliferation by
targeting miR-139-3p/HMGB1 signaling axis [28], and
circ_0001667 could enhance BC cell survival by regulating
TAZ in Hippo signal pathway [29]. In our study, we also
demonstrated the upregulation of CircPRMT5 in BC
tumors and cell lines, and the silencing of CircPRMT5
suppressed the aggressive phenotype of BC cells. We
therefore propose that CircPRMT5 may function as an
oncogene in BC development.
CircPRMT5 is one of the circRNAs whose abnormal
expression has been documented in a variety of malignant
tumor tissues. circPRMT5 is highly expressed in gastric
cancer patients, and the upregulation of circPRMT5
can promote the expression of oncogene MYC through
sponging miR-145 and miR-1304 [30]. In bladder cancer,
overexpressed circPRMT5 regulates the epithelialmesenchymal transition of bladder cancer cells and
promotes the metastasis [13]. Moreover, the expression
level of circPRMT was also elevated in esophageal cancer
cells to augment the migration [31]. In hepatoma and
nonsmall cell lung cancer (NSCLC), upregulation of
circPRMT5 facilitates cancer progression via targeting
HK2 or EZH2 [15,16]. Therefore, it seems that circPRMT5
plays multifaceted roles by targeting different pathways to
support tumorigenesis in different cancers.
In line with these previous findings, our present
study showed that the expression level of circPRMT5
is significantly increased in human BC tissues, serum
samples of BC patients and BC cells. High expression
of circPRMT5 is associated with a poorer prognosis in
BC patients. These findings are consistent with a recent
study in which the upregulation of circPRMT5 in breast
cancer cells contributes to the aggressive phenotype by
mediating the miR-509-3p/TCF7L2 axis to activate the
PI3K/AKT pathway [32]. Apart from that, our study
further demonstrated that circPRMT5 is indispensable
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for the invasion and migration capabilities of BC cells.
Furthermore, the clinical parameter analysis showed that
a high circPRMT5 expression level is correlated with
larger tumor size, more advanced TNM stage, poorer
differentiation, and more lymph node metastasis distant
metastasis. Together, our results and the recent study
highlighted a functional role of circPRMT5 in supporting
the malignant phenotype in BC cells. However, but no
correlation was observed between circPRMT5 and ER,
PR, HER2 status, indicating that the upregulation of
circPRMT5 in BC may not result from dysregulated
hormone receptor signaling.
To sum up, our study found that circPRMT5 is highly
expressed in BC tumor and the plasma of BC patients.
The higher circPRMT5 expression level is related to more
aggressive tumor phenotypes including more advanced
tumor staging, lymph node metastasis, and poorer
differentiation in tumor. Our data suggest that circPRMT5
might be a potential diagnostic and prognostic biomarker
for BC. However, this study is limited to the analysis
of clinical samples and the functional assays in cell

experiments. Further experiments are needed to validate
the tumorigenic role of circPRMT5 in BC animal model
and to elucidate the molecular targets of circPRMT5.
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